The therapeutic potential of cannabis in multiple sclerosis (Q35094657)

6 August 2017

1 reference

title

The therapeutic potential of cannabis in multiple sclerosis (English)

1 reference

6 August 2017

0 references

David Baker

1

1 reference

6 August 2017

Gareth Pryce

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

561-567

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

6 August 2017

1 reference

The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Cannabinoids in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

The functional neuroanatomy of brain cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Molecular biology of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Brain monoglyceride lipase participating in endocannabinoid inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Endocannabinoid signaling in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Cannabinoid receptors and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

21 January 2018

Cannabinoid analgesia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

21 January 2018

Cannabis and psychosis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Cannabinoids control spasticity and tremor in a multiple sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Immunotherapy of multiple sclerosis: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Endocannabinoids in the immune system and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Leptin-regulated endocannabinoids are involved in maintaining food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Requirement for leptin in the induction and progression of autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

Cannabinoids and cell fate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

The therapeutic potential of the cannabinoids in neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

CB(1) receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.561

10.1517/13543784.12.4.561

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference